In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, offers a synopsis on what questions cell and gene therapy developers need to answer to ...

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market ...

Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers. Novartis announced that it has acquired Mariana Oncology, a biotech specializing in ...

In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses which skills or experiences he thinks are most valuable for team members tasked with ...

Poseida Therapeutics announced that it has entered into a partnership with Xyphos, a wholly owned subsidiary of Astellas. 1 The two companies will work together to develop a type of cancer treatment ...

The plan is focused on providing financial incentives for treatments that improve the patients’ health equity.

A Harvard Business School Healthcare Alumni Association Q&A with Matt Wolf, president of Biopharma Services at Cencora.

Jude Dieterman, CEO of Outcomes, spoke with Pharmaceutical Executive about the role local pharmacies are playing in improving health equity issues. According to him, these local establishments can ...

Currently in Phase III of clinical trials, eneboparatide has shown promise in normalizing key calcium levels and improving ...

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses the changing ...

The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...

In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses specific ...